Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ANTHIM vs BEYFORTUS
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Oblimersen is an antisense oligonucleotide that inhibits the production of Bcl-2 protein, promoting apoptosis in cancer cells.
BEYFORTUS (nirsevimab) is a recombinant human monoclonal antibody that binds to the prefusion conformation of the respiratory syncytial virus (RSV) F protein, inhibiting viral entry into host cells by blocking the fusion of the viral envelope with the host cell membrane.
FDA: Treatment of chronic lymphocytic leukemia (CLL) (not approved; withdrawn from market),Off-label: None
Prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants entering their first RSV season, and in children up to 24 months of age who remain vulnerable through their second RSV season.
800 mg IV over 90 minutes, then 400 mg IV over 90 minutes at 2 and 4 weeks post-first dose.
Not applicable; BEYFORTUS (nirsevimab) is indicated for prevention of respiratory syncytial virus lower respiratory tract disease in neonates and infants. No adult dose exists.
Terminal elimination half-life: approximately 21 days (range 12–31 days); supports monthly dosing for post-exposure prophylaxis
Terminal elimination half-life is approximately 26.8 days in infants, supporting season-long protection after a single dose.
Metabolized by exonucleases to shorter oligonucleotides.
Nirsevimab is degraded via catabolic pathways into small peptides and amino acids.
Renal: approximately 50% as unchanged drug; biliary/fecal: minimal (<10%)
Beyfortus (nirsevimab) is eliminated primarily via catabolism to small peptides and amino acids. No specific data on renal or biliary excretion; expected to undergo proteolytic degradation with minimal renal or fecal elimination of intact drug.
Approximately 57% bound to plasma proteins (including albumin and immunoglobulins)
Protein binding is approximately 99.5%, primarily to albumin.
Volume of distribution: approximately 0.16–0.20 L/kg; indicates limited extravascular distribution, consistent with a monoclonal antibody
Volume of distribution is approximately 4.5 L in infants (mean Vd ≈ 0.3 L/kg), indicating distribution primarily in plasma and interstitial fluid.
Intravenous: 100% bioavailability; no other routes are approved or clinically relevant
Bioavailability after intramuscular injection is approximately 70-80% (absolute bioavailability not established; relative to IV data).
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Insufficient data for severe renal impairment (Cr Cl <30 m L/min) or ESRD.
No dosage adjustment required for renal impairment; nirsevimab is a monoclonal antibody not renally cleared.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Insufficient data for severe hepatic impairment (Child-Pugh C).
No dosage adjustment required for hepatic impairment; nirsevimab is a monoclonal antibody not hepatically metabolized.
For patients weighing 10 kg to <40 kg: 14 mg/kg IV (max 800 mg) over 90 minutes, then 7 mg/kg IV (max 400 mg) over 90 minutes at 2 and 4 weeks post-first dose. For patients ≥40 kg: same as adult dosing.
Neonates and infants weighing <5 kg: 50 mg intramuscular (IM) single dose; infants weighing ≥5 kg: 100 mg IM single dose. Administer during RSV season.
No specific dose adjustment recommended; clinical studies did not include sufficient numbers of patients aged ≥65 years to determine whether they respond differently. Use with caution.
Not indicated for geriatric population; no dosing recommendations available.
None.
No black box warning.
Myelosuppression,Infusion reactions,Tumor lysis syndrome,Electrolyte abnormalities,Cardiotoxicity
Hypersensitivity reactions including anaphylaxis have been reported.,Use caution in patients with thrombocytopenia or any coagulation disorder due to risk of bleeding from intramuscular injection.
Hypersensitivity to oblimersen or any component of the formulation
History of serious hypersensitivity reaction to nirsevimab or any component of the formulation.
No known food interactions. ANTHIM is administered intravenously, and food intake does not affect its pharmacokinetics.
No known food interactions. BEYFORTUS is administered by intramuscular injection and does not interact with dietary components.
ANTHIM (obiltoxaximab) is a monoclonal antibody. Embryo-fetal developmental studies in monkeys showed no adverse effects at doses up to 17 times the human dose. However, human data is limited. As a Ig G1 monoclonal antibody, it is expected to cross the placenta increasingly after the first trimester. The risk is likely low but cannot be excluded. Use only if clearly needed.
BEYFORTUS (nirsevimab) is a human monoclonal antibody against respiratory syncytial virus. There are no adequate and well-controlled studies in pregnant women. In animal reproduction studies, no adverse developmental effects were observed in pregnant rabbits or cynomolgus monkeys at doses up to 10 times the human clinical exposure. However, because monoclonal antibodies are transported across the placenta in increasing amounts as pregnancy progresses (especially in the third trimester), potential fetal exposure may occur. Based on limited data, the risk of major birth defects and miscarriage is unknown but expected to be low due to the Ig G1 nature and lack of known teratogenic signal.
It is not known whether obiltoxaximab is excreted in human milk. Monoclonal antibodies are typically excreted in breast milk at low levels with limited oral bioavailability due to gastrointestinal degradation. The M/P ratio is unknown. Caution should be exercised, but benefits of breastfeeding and maternal therapy should be considered.
There are no data on the presence of nirsevimab in human milk, effects on the breastfed infant, or effects on milk production. Nirsevimab is a human monoclonal antibody (Ig G1) and is expected to be excreted into human milk in small amounts due to the high molecular weight and limited transfer via the neonatal Fc receptor. The M/P ratio has not been determined. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for BEYFORTUS and any potential adverse effects on the breastfed infant from the drug or underlying condition.
No dose adjustment is required for ANTHIM based on pregnancy. Pharmacokinetic studies in pregnant women are not available; however, pregnancy-related changes in volume of distribution and renal clearance may alter drug levels, but clinical significance is unknown. Standard adult dosing is recommended.
No dosing adjustments are required for BEYFORTUS during pregnancy. Pregnancy-related physiological changes (e.g., increased plasma volume, altered renal clearance) are not expected to significantly affect the pharmacokinetics of a monoclonal antibody administered intramuscularly, as nirsevimab has a long half-life and is not renally excreted. The standard single dose of 50 mg (for infants <5 kg) or 100 mg (for infants ≥5 kg) is recommended regardless of pregnancy status.
ANTHIM (obiltoxaximab) is a monoclonal antibody indicated for inhalational anthrax. It should be administered as soon as possible after suspected or confirmed exposure. Premedication with diphenhydramine may reduce infusion reactions. Monitor for anaphylaxis and infusion-related reactions. Efficacy is established in animal models due to ethical limitations.
BEYFORTUS (nirsevimab) is a recombinant human monoclonal antibody for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants. It is administered as a single intramuscular injection, typically 50 mg for infants <5 kg and 100 mg for infants ≥5 kg. It is not a treatment for active RSV infection. It does not interfere with live attenuated vaccines; however, administration with other injectable vaccines at different sites is acceptable. Do not administer to infants with a history of severe hypersensitivity to nirsevimab or any excipients. Efficacy has not been established in infants with a history of RSV infection.
ANTHIM is used to treat or prevent inhalational anthrax, which can be fatal if not treated.,You will receive this medication as an intravenous (IV) infusion over 1.5 hours.,You may experience side effects such as pain or swelling at the infusion site, headache, itching, or feeling tired.,Serious allergic reactions can occur; tell your healthcare provider immediately if you develop rash, hives, difficulty breathing, or swelling of the face or throat.,Because ANTHIM is made from mouse proteins, it can cause allergic reactions in some people.,This medication should not replace a recommended vaccination program for anthrax.
This vaccine is given as a single shot to prevent serious RSV disease in your infant.,It is not a treatment for active RSV infection; if your infant has RSV symptoms, inform the healthcare provider.,Common side effects include injection site reactions, rash, and fever. Contact your provider if these persist or worsen.,Inform the healthcare provider of any allergic reactions or bleeding disorders before administration.,Your infant can still receive other vaccines as scheduled.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ANTHIM vs BEYFORTUS, answered by our medical review team.
ANTHIM is a Monoclonal Antibody that works by Oblimersen is an antisense oligonucleotide that inhibits the production of Bcl-2 protein, promoting apoptosis in cancer cells.. BEYFORTUS is a Monoclonal Antibody for RSV Prophylaxis that works by BEYFORTUS (nirsevimab) is a recombinant human monoclonal antibody that binds to the prefusion conformation of the respiratory syncytial virus (RSV) F protein, inhibiting viral entry into host cells by blocking the fusion of the viral envelope with the host cell membrane.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ANTHIM and BEYFORTUS depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ANTHIM is: 800 mg IV over 90 minutes, then 400 mg IV over 90 minutes at 2 and 4 weeks post-first dose.. The standard adult dose of BEYFORTUS is: Not applicable; BEYFORTUS (nirsevimab) is indicated for prevention of respiratory syncytial virus lower respiratory tract disease in neonates and infants. No adult dose exists.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ANTHIM and BEYFORTUS in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ANTHIM is classified as Category C. ANTHIM (obiltoxaximab) is a monoclonal antibody. Embryo-fetal developmental studies in monkeys showed no adverse effects at doses up to 17 times the human dose. However, human data. BEYFORTUS is classified as Category C. BEYFORTUS (nirsevimab) is a human monoclonal antibody against respiratory syncytial virus. There are no adequate and well-controlled studies in pregnant women. In animal reproducti. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.